Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
| Autor: | Lam, S.W., de Groot, S.M., Honkoop, A.H., Jager, A., ten Tije, A.J., Bos, M.M.E.M., Linn, S.C., van den Bosch, J., Kroep, J.R., Braun, J.J., van Tinteren, H., Boven, E. |
|---|---|
| Zdroj: | In European Journal of Cancer December 2014 50(18):3077-3088 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect